Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist

Neuropsychopharmacology

Volumn 33, Issue 9, 2008, Pages 2206-2216

  Benneyworth, Michael A ^a   Smith, Randy L ^a   Sanders Bush, Elaine ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT 2A; Chronic treatment; Drug discrimination; Hallucinogen; Head twitch; mGlu2 3

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BROLAMFETAMINE; EGLUMETAD; LYSERGIDE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; PHENCYCLIDINE; PHENETHYLAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HEAD TWITCH; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS, HETEROCYCLIC; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXCITATORY AMINO ACID AGONISTS; EXPLORATORY BEHAVIOR; FLUOROBENZENES; HALLUCINOGENS; LOCOMOTION; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; MICE, INBRED ICR; PHENETHYLAMINES; PIPERIDINES; PSYCHOTROPIC DRUGS; TIME FACTORS;

EID: 47249134188     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301600     Document Type: Article

References (49)

1. Abdul-Monim Z, Neill J, Reynolds G (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alteration in parvalbumin-immunoreactive expression in the rat. J Psychopharm 21: 198-205.
2. Abdul-Monim Z, Reynolds G, Neill J (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169: 263-273.
3. Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589-599.
4. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825: 161-171.
5. Aghajanian GK, Marek GJ (2000). Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31: 302-312.
6. Appel J, White F, Holohean A (1982). Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures. Neurosci Behav Rev 6: 529-536.
7. Benneyworth MA, Smith RL, Barrett RJ, Sanders-Bush E (2005). Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice. Psychopharmacology (Berl) 179: 854-862.
8. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (2007). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharm 72: 477-484.
9. Cartmell J, Monn JA, Schoepp DD (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
10. Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R et al (1989). Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 28: 119-133.
11. Colpaert FC (1999). Drug discrimination in neurobiology. Pharmacol Biochem Behav 64: 337-345.
12. Conn PJ, Pin J (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
13. Dunn M, Killcross S (2006). Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance. Behav Brain Res 175: 271-277.
14. Ebmeier KP, Lawrie SM, Blackwood DH, Johnstone EC, Goodwin GM (1995). Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia. J Neurol Neurosurg Psychiatry 58: 452-456.
15. 2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology 121: 347-356.
16. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315: 1181-1187.
17. Gewirtz JC, Marek GJ (2000). Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23: 569-576.
18. Glennon RA, Titeler M, McKenney JD (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505-2511.
19. Glennon RA, Young R, Rosecrans JA (1983). Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91: 189-196.
20. Gonzalez-Maeso J, Wiesstaub N, Zhou M, Chan P, Ivic L, Ang R et al (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439-452.
21. Gresch PJ, Barrett RJ, Sanders-Bush E, Smith RL (2007). Serotonin-2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of lysergic acid diethylamide. J Pharmacol Exp Ther 320: 662-669.
22. Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E et al (1992). Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32: 976-991.
23. Javitt D, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29: 300-307.
24. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES et al (1993). Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 11: 47-54.
25. Klodzinska A, Bijak M, Tokarski K, Pilc A (2002). Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73: 327-332.
26. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303-309.
27. Lindahl J, Keifer J (2004). Glutamate receptor subunits are altered in forebrain and cerebellum in rats chronically exposed to the NMDA receptor antagonist phencyclidine. Neuropsychopharmacology 29: 2065-2073.
28. Lorrain D, Baccei C, Bristow L, Anderson J, Varney M (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
29. Marek G, Wright R, Schoepp D (2006). 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci Lett 403: 256-260.
30. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000). Physiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292: 76-87.
31. Moghaddam B, Adams B (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
32. Muschamp JW, Regina MJ, Hull EM, Winter JC, Rabin RA (2004). Lysergic acid diethylamide and (-)-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res 1023: 134-140.
33. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
34. 2 agonist-induced Arc gene expression in the rat cortex. Neuropharmacology 46: 331-339.
35. Rujescu D, Bender A, Keck M, Hartmann A, Ohl F, Raeder H et al (2006). A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional, and behavioral abnormalities. Biol Psychiatry 59: 721-729.
36. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273: 101-112.
37. 2A heteroreceptors on thalamocortical glutamatergic neurons. J Neurosci 20: 8846-8852.
38. Scruggs JL, Schmidt D, Deutch AY (2003). The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci Lett 346: 137-140.
39. Smith RL, Barrett RJ, Sanders-Bush E (2003). Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 166: 61-68.
40. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94: 213-216.
41. Vollenweider FX, Geyer MA (2001). A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507.
42. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J et al (1997a). Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7: 9-24.
43. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997b). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372.
44. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998). Psilocybin induces schizoprenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
45. Willins DL, Meltzer HY (1997). Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282: 699-706.
46. Winter JC, Eckler JR, Rabin RA (2004). Serotonergic/glutamatergic interactions: the effects of mGluR2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172: 233-240.
47. Winter JC, Kieres AK, Zimmerman MD, Reissig CJ, Eckler JR, Ullrich T et al (2005). The stimulus properties of LSD in C57BL/6 mice. Pharmacol Biochem Behav 81: 830-837.
48. Xi Z, Ramamoorthy S, Baker D, Shen H, Samuvel D, Kalivas P (2002). Modulation of group II metabotropic glutamate receptors signaling by chronic cocaine. J Pharmacol Exp Ther 303: 608-615.
49. Zhai Y, Carolyn GA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK (2003). Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28: 45-52.